论文部分内容阅读
总结了更昔洛韦防治肾移植患者巨细胞病毒（Ｃｙｔｏｍｅｇａｌｏｖｉｒｕｓ，ＣＭＶ）感染的研究结果。预防研究共１５３例，更昔洛韦组８８例，阿昔洛韦组６５例。两组预防ＣＭＶ疾病的效果有明显差异（９．１％ｖｓ２４．６％，Ｐ＜０．０５），而预防ＣＭＶ活动性感染的效果无明显差异（２０．４％ｖｓ１５．６％，Ｐ＞０．０５），但更昔洛韦组ＣＭＶ活动性感染的持续时间明显短于阿昔洛韦组（２～６周ｖｓ３～９周，Ｐ＜０．０１）。治疗ＣＭＶ肺炎３１例，更昔洛韦组１５例治愈率８０％；阿昔洛韦组１６例治愈率２５％（Ｐ＜０．０５）。认为更昔洛韦能有效预防ＣＭＶ疾病，缩短活动性感染的持续时间，对ＣＭＶ疾病有比较满意的治疗效果。
The research results of ganciclovir in prevention and treatment of cytomegalovirus (CMV) infection in renal transplant recipients were summarized. There were 153 prevention studies, 88 with ganciclovir and 65 with acyclovir. There was significant difference between the two groups in preventing CMV disease (9.1% vs24.6%, P <0.05), while there was no significant difference in the prevention of CMV infection (20.4% vs15.6%, P> 0.05). However, the duration of CMV infection in ganciclovir group was significantly shorter than that in acyclovir group (2-6 weeks vs 3-9 weeks, P <0.01). 31 cases were treated with CMV pneumonia and 15 cases with ganciclovir were cured with a cure rate of 80%. In the acyclovir group, the cure rate was 25% (P <0.05). It is considered that ganciclovir can effectively prevent CMV disease, shorten the duration of active infection and have satisfactory therapeutic effect on CMV disease.